Original Sky Meter Intranet
Highlights
Recently, the National Pharmacopoeia Commission (ChPC) issued a public announcement to revise the national drug standards for musk baoxin pills. The product is the exclusive myocardial infarction treatment drug of Shanghai Hutchison Pharmaceutical, with a total sales of more than 2.9 billion yuan in 2023 in China's three major terminal and six major markets. Since the beginning of this year, the ChPC official website has published at least 24 draft national drug standards for proprietary Chinese medicines, of which exclusive varieties account for 62%.
Source: ChPC official website
Musk Baoxin Pill is mainly composed of artificial musk, ginseng extract, artificial bezoar, cinnamon, Suhexiang, toad crisp, borneol, etc., the main function is aromatic and warm, invigorating qi and strengthening the heart, and is used for chest paralysis caused by qi stagnation and blood stasis, and the symptoms are pain in the precordial area, which is fixed and unmovable; Angina pectoris and myocardial infarction caused by myocardial ischemia are seen in the above syndromes, which are national basic drugs and national medical insurance Class A drugs.
According to data from Minenet, Musk Baoxin Pill is the exclusive myocardial infarction treatment drug of Shanghai Hutchison Pharmaceutical, with a total market size of more than 2.9 billion yuan in China's three major terminal and six major markets in 2023 (see the statistical scope at the end of this article for details), a year-on-year increase of 8.97%; Among them, the terminal of public medical institutions is the main sales battlefield of the drug, with a market share of more than ninety percent, and it ranks fourth among the Chinese patent medicine products for cardiovascular and cerebrovascular diseases.
In recent years, the sales trend of musk baoxin pills in China's three major terminals and six major markets (unit: 10,000 yuan)
Source: Minenet Grid Bureau Database
Since the beginning of this year, ChPC has publicized at least 24 draft national drug standards for Chinese patent medicines, of which exclusive varieties account for 62%, including Buchang Pharmaceutical's Difeng Pain Relief Capsule and Wenxin Granules, Taiji Group's Yinqi Liver Complex Granules, Kangyuan Pharmaceutical's Qige Oral Liquid, etc.; According to the statistics of treatment subcategories, drugs for rheumatic diseases and drugs for cardiovascular diseases led the way in terms of quantity with 4 and 3 products respectively, followed by drugs for liver diseases, drugs for strengthening the waist and kidneys and drugs for cerebrovascular diseases with 2 products each.
List of National Drug Standard Proprietary Chinese Medicines published by ChPC since 2024 (with * is an exclusive variety)
Source: Minenet database, ChPC official website
Note: The statistical scope of "Drug Competition Pattern of China's Three Terminals and Six Major Markets" by Minenet is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, and county and rural pharmacies; The above sales are calculated based on the average retail price of the product at the terminal. The statistics are as of May 14, if there is any omission, please correct!